Recent Updates — PLRZ
Polyrizon Ltd. filed its interim condensed financial statements and management discussion for the six months ended June 30, 2026. The company reported a net loss of $1.4 million, with cash and cash equivalents increasing to $8.4 million from proceeds of a $3.5 million registered direct offering closed on April 8, 2026. Subsequent to the balance sheet date, Polyrizon exercised warrants for Quantum X Labs Inc. shares on July 2, 2026, and closed another registered direct offering with gross proceeds of approximately $4.0 million on September 4, 2026. The company also announced a reverse share split effective November 28, 2025, at a ratio of one-for-6. Polyrizon Ltd. is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment against viruses and allergens.
Polyrizon Ltd. closed a registered direct offering and concurrent private placement on September 4, 2026, raising approximately $4.0 million in aggregate gross proceeds from a single institutional investor. The company issued 333,333 units at a combined price of $12.00 per unit, consisting of ordinary shares and pre-funded warrants alongside common warrants with an exercise price of $12.00. Net proceeds will be used for general corporate purposes and working capital. Polyrizon Ltd. is a development-stage biotech company specializing in innovative intranasal hydrogels delivered via nasal sprays.
On September 3, 2026, Polyrizon Ltd. entered into a securities purchase agreement to raise approximately $4.0 million through a registered direct offering and concurrent private placement with a single institutional investor. The company sold 232,500 ordinary shares at $12.00 per share in the registered direct offering. In the private placement, it issued 70,833 pre-funded warrants exercisable at $0.00001 and 333,333 ordinary share warrants with a $12.00 exercise price and five-year term. Aegis Capital Corp. served as the sole placement agent for an aggregate fee of 8.0% plus expenses. The transactions are expected to close on or about September 4, 2026, with proceeds designated for general corporate purposes, working capital, and strategic acquisitions. Polyrizon Ltd. is a development-stage biotech company specializing in innovative intranasal hydrogels delivered via nasal sprays.
Polyrizon Ltd. announced on August 20, 2026, that it has completed contracting with all five U.S. clinical sites for the NASARIX™ Allergy Blocker (PL-14) study. This milestone advances the first-in-human trial toward patient enrollment of up to 120 subjects assigned in a 1:1 ratio to receive either the treatment or an isotonic saline control. The multicenter, randomized, single-blind trial aims to evaluate efficacy and safety for seasonal allergic rhinitis, with primary endpoints focusing on mean daily reflective Total Nasal Symptom Scores over 14 days. Patient recruitment will align with relevant allergy seasons based on local pollen counts. Polyrizon is a development-stage biotech company specializing in innovative intranasal hydrogels.